Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Similar to lung and pancreatic -cells (24), mice peritoneal macrophages and vascular smooth muscle cells abundantly expressed GLP-1 receptor protein, and the expression level was higher than in freshly isolated endothelial cells.”
ResultGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575 · cited 1×
“Both TNF- – and MCP-1–deficient mice have significantly reduced atherosclerotic lesions (29,30).”
BackgroundA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217 · cited 2×
“The adhesion of circulating monocytes to the intimal endothelial cells is thought to be one of the earliest events in the complex pathological process of atherosclerogenesis (14; 15).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“In vascular endothelial cells, GLP-1 stimulates NO production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundEbato, C., Uchida, T., Arakawa, M., Komatsu, M., Ueno, T., Komiya, K., Azuma, K., Hirose, T., Tanaka, K., Kominami, E., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.009 · Cited by 774 · cited 2×
“) or rabbit anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling Technology, Beverly, MA) as described previously (16).”
BackgroundMethodSelf-citationNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
Background
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“This results in a reduction of monocyte accumulation in the vascular wall, as shown for example with exenatide [143].”
BackgroundChait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Autophagy—a key player in cellular and body metabolism
Kim, K. H., & Lee, M.-S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.35 · Cited by 963
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading
Pols, T. W. H., Nomura, M., Harach, T., Lo Sasso, G., Oosterveer, M. H., Thomas, C., Rizzo, G., Gioiello, A., Adorini, L., Pellicciari, R., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.006 · Cited by 610
“, 2008a), was recently shown to protect against atherosclerosis via a mechanism that involves cAMP induction in macrophages (Arakawa et al., 2010).”
BackgroundGlucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
“GLP-1R has been localized to mouse aortic smooth muscle and endothelial cells, as well as monocytes and macrophages, using immunocytochemistry and Western blotting (140).”
MethodAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17], suggesting that GLP-1 might have additional roles other than glucoselowering effects.”
BackgroundMarx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
“[37] reported an antiinflammatory effect of exendin-4 in an animal model of atherosclerosis.”
BackgroundAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
“Taspoglutide treatment of ApoE / mice The results of previous studies demonstrated that continuous GLP-1 or exendin-4 administration attenuated the development of atherosclerosis in normoglycemic ApoE / mice (7, 10).”
InfluentialCentral effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
“…exendin-4 can reduce monocyte adhesion to aortic endothelium in an inflammatory response in atherosclerosis and also prevents LPS-induced cytokine and chemokine release in both human and mouse monocytes (Arakawa et al. 2010) and an increase in microvascular permeability (Dozier et al. 2009).”
BackgroundGLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
“Recently, mice carrying null mutation for the c-Rel gene, a regulatory subunit of the transcriptional regulator of inflammation NFκB, have been characterized and suggested to be a useful model of progressive inflammation-induced nigral degeneration (Baiguera et al., 2012). c-Rel KO mice develop an age-dependent PD-lik…”
BackgroundInfluentialExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Helmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000615456.97862.30 · Cited by 283
Janus, A., Szahidewicz-Krupska, E., Mazur, G., & Doroszko, A. (2016) · Mediators of Inflammation · doi:10.1155/2016/3634948 · Cited by 271
“In animal models GLP-1 agonist diminished monocyte adhesion, macrophage infiltration, and atherosclerotic lesions in the vasculature [75].”
Worthington, J. J., Reimann, F., & Gribble, F. M. (2018) · Mucosal Immunology · doi:10.1038/mi.2017.73 · Cited by 262
Matsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama, E., Kurokawa, H., Nozaki, T., Ohba, K., Konishi, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.053 · Cited by 273
“(4) showed that the GLP-1 receptor agonist exendin-4 reduced atherosclerotic lesion in mice and that this effect may contribute to the inhibition of NF- B p65 nuclear translocation in macrophages by increased cAMP levels elicited by GLP-1 receptor activation.”
BackgroundNagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259
“[5] reported that exendin-4 suppresses the lipopolysaccharide-induced mRNA expression of TNF-α (also known as TNF) and MCP1 via the cAMP/PKA pathway.”
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259
“This peptide and its analogs also exert cytoprotective actions, 12 with GLP-1 receptor (GLP-1R) activation resulting in reduced inflammation in atherosclerotic lesions, 13 brain, 14 and pancreatic β -cells.”
BackgroundSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
“These effects were significantly blocked by the GLP-1 antagonist, exendin (9-39)(120).”
BackgroundInfluentialShirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
“Furthermore, exendin-4 inhibited monocyte adhesion to endothelial cells (16) and GLP-1 receptor signaling affected lymphocyte proliferation (17).”
BackgroundHendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Endothelial Dysfunction and Diabetic Cardiomyopathy
Wang, M., Li, Y., Li, S., & Lv, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851941 · Cited by 207
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
Diabetes and Lung Disease: An Underestimated Relationship
Khateeb, J., Fuchs, E., & Khamaisi, M. (2019) · Review of Diabetic Studies · doi:10.1900/rds.2019.15.1 · Cited by 198
Gaspari, T., Liu, H., Welungoda, I., Hu, Y., Widdop, R. E., Knudsen, L. B., Simpson, R. W., & Dear, A. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404257 · Cited by 202
“The improvement in endothelial-dependent relaxation evoked by liraglutide was completely abolished in mice cotreated with exendin (9-39) (R max = 53.”
BackgroundMethodGlucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., & Takeya, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.086 · Cited by 208
The regulation of food intake by the gut-brain axis: implications for obesity
Hussain, S. S., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.93 · Cited by 195
Satoh-Asahara, N., Sasaki, Y., Wada, H., Tochiya, M., Iguchi, A., Nakagawachi, R., Odori, S., Kono, S., Hasegawa, K., & Shimatsu, A. (2013) · Metabolism · doi:10.1016/j.metabol.2012.09.004 · Cited by 198
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191
“More recently, it has been shown that exendin-4, a GLP-1R agonist, can reduce monocyte adhesion to aortic endothelium in a model of atherosclerosis and prevent LPS-induced cytokine and chemokine mRNA synthesis in both human and mouse monocytes([88]) and also reduces an LPSinduced increase in microvascular permeability.”
BackgroundWiniarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Balestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., et al. (2015) · Diabetes · doi:10.2337/db14-1149 · Cited by 196
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
MethodIncretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 189
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
“The other report demonstrated that exendin-4 inhibits monocyte adhesion to endothelial cells and attenuates atherosclerotic lesions in apolipoprotein E-deficient mice, in which exendin-4 suppressed NF-κB activation in macrophages [17].”
RetractedPathophysiology of Non Alcoholic Fatty Liver Disease
Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Svegliati-Baroni, G., Valenti, L., & Bonino, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122082 · Cited by 170
“One potential mechanism by which GLP-1 may play a nephro-protective role is its natriuretic activity, due to the direct inhibition of two key sodium transporters (Na-hydrogen exchanger-3 and sodium-glucose co-transporter-2) at the tubular level [124].”
BackgroundWang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., et al. (2013) · Diabetes · doi:10.2337/db12-1025 · Cited by 179
Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease
He, S., Kahles, F., Rattik, S., Nairz, M., McAlpine, C. S., Anzai, A., Selgrade, D., Fenn, A. M., Chan, C. T., Mindur, J. E., et al. (2019) · Nature · doi:10.1038/s41586-018-0849-9 · Cited by 167
Ervinna, N., Mita, T., Yasunari, E., Azuma, K., Tanaka, R., Fujimura, S., Sukmawati, D., Nomiyama, T., Kanazawa, A., Kawamori, R., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1855 · Cited by 167
Self-citationBatchuluun, B., Inoguchi, T., Sonoda, N., Sasaki, S., Inoue, T., Fujimura, Y., Miura, D., & Takayanagi, R. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.10.025 · Cited by 161
Wronkowitz, N., Görgens, S. W., Romacho, T., Villalobos, L. A., Sánchez‐Ferrer, C. F., Peiró, C., Sell, H., & Eckel, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.004 · Cited by 159
Mita, T., Katakami, N., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0781 · Cited by 159
Self-citationDefective autophagy in vascular smooth muscle cells enhances cell death and atherosclerosis
Osonoi, Y., Mita, T., Azuma, K., Nakajima, K., Masuyama, A., Goto, H., Nishida, Y., Miyatsuka, T., Fujitani, Y., Koike, M., et al. (2018) · Autophagy · doi:10.1080/15548627.2018.1501132 · Cited by 149
“The supernatants were subjected to Western blot analysis using primary antibodies, as follows: guinea pig antihuman SQSTM1/p62 antibody (Progen Biotechnik GmbH, GP62-C), rabbit anti-MAP1LC3B/LC3 antibody (SigmaAldrich, L7543), mouse anti-TRP53 (1C12) antibody (Cell Signaling Technology, 2524), rabbit anti-phospho-TRP5…”
MethodSelf-citationTashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Hölscher, C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15508 · Cited by 155
“…can reduce monocyte adhe- sion to the aortic endothelium in an inflammation response in athero- sclerosis and also prevents lipopolysaccharide (LPS)-induced cytokine and chemokine release (Arakawa et al., 2010) and can prevent an increase in microvascular permeability (Dozier et al., 2009).”
BackgroundGaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148
The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 156
“Preclinical studies One study reported that exendin-4 inhibited monocyte adhesion in the aorta of C57BL/6 (control) mice, as well as markedly reducing the accumulation of monocytes and macrophages in the vascular wall and suppressing the development of atherosclerosis in apolipoprotein E (apoE)-knockout C57BL/6 mice,…”
BackgroundGlucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Cameron-Vendrig, A., Adili, R., Siraj, M. A., Xu, X., Wang, Y., Lei, X., Afroze, T., Shikatani, E. A., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 149
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P. G., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M. D., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 149
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., et al. (2014) · Diabetes · doi:10.2337/db13-1169 · Cited by 147
“Indeed, the vascular protective effects of exendin (Ex)-4, a GLP-1R agonist, have been demonstrated by the attenuation of atheroma formation in apoE mice via inhibition of nuclear factor-kB activation in macrophages (4) and by the reduction in intimal thickening after vascular injury via 59 AMPK activation in vascular…”
BackgroundMethodSelf-citationThe Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & CHILTON, R. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 144
“A recent study in mice has also suggested that exenatide reduces macrophage adhesion to the endothelium, the key initiating step in formation of atherosclerotic plaques [27].”
BackgroundLuna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernández-Reyes, M., Apostolova, N., Vila, J. M., Solá, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 141
Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137
Vinué, Á., Navarro, J., Herrero-Cervera, A., García-Cubas, M., Andrés-Blasco, I., Martínez-Hervás, S., Real, J. T., Ascaso, J. F., & González-Navarro, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4330-3 · Cited by 137
“Previous studies have shown that liraglutide treatment decreases atherosclerosis in Apoe mice [12, 28, 29] and in LDL-receptor-deficient mice [30] but also improves endothelial dysfunction [31–33].”
BackgroundMita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Onuma, T., Kuribayashi, N., Osonoi, T., Kaneto, H., Kosugi, K., Umayahara, Y., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2145 · Cited by 136
“a-Glucosidase inhibitor 41 (30) 42 (31) 1.”
BackgroundSelf-citationViby, N., Isidor, M. S., Buggeskov, K. B., Poulsen, S. S., Hansen, J. B., & Kissow, H. (2013) · Endocrinology · doi:10.1210/en.2013-1666 · Cited by 134
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.004 · Cited by 132
“[40] Arakawa M, Mita T, Azuma K, et al.”
BackgroundThe benefits of GLP1 receptors in cardiovascular diseases
Ferhatbegović, L., Mršić, D., & Macić-Džanković, A. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1293926 · Cited by 127
Wang, Y., Parlevliet, E. T., Geerling, J. J., van der Tuin, S. J. L., Zhang, H., Bieghs, V, Jawad, A. H. M., Shiri‐Sverdlov, R., Bot, I., de Jager, S. C. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12490 · Cited by 126
“Our results add to previous findings demonstrating that 4 weeks of GLP-1 receptor activation decreases atherosclerotic development without reducing plasma lipids in ApoE−/− mice (Arakawa et al., 2010; Nagashima et al., 2011; Gaspari et al., 2013).”
BackgroundResultInfluentialZhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H. M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X. Y., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 141
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 132
Zeng, Y., Li, C., Guan, M., Zheng, Z., Li, J., Xu, W.-W., Wang, L., He, F., & Xue, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-32 · Cited by 122
“It was previously reported that most of the anti-atherosclerotic effects of GLP-1 and DPP-4 inhibitors may be mediated through the activation of intracellular cyclic AMP (cAMP) and protein kinase A (PKA) signaling [6,12].”
BackgroundGLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Park, B., Bakbak, E., Teoh, H., Krishnaraj, A., Dennis, F., Quan, A., Rotstein, O. D., Butler, J., Hess, D. A., & Verma, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00574.2023 · Cited by 130
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Parthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.012 · Cited by 119
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 132
“Administration of the DPP-4-resistant GLP-1 analog exendin-4 to apoE-deficient mice, which spontaneously develop atherosclerosis, diminished atherosclerotic lesion size and monocyte/macrophage recruitment to the vascular wall independent of changes in plasma lipid levels or glucose tolerance [95].”
BackgroundDai, Y., Mehta, J. L., & Chen, M. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6463-z · Cited by 117
Goto, H., Nomiyama, T., Mita, T., Yasunari, E., Azuma, K., Komiya, K., Arakawa, M., Jin, W. L., Kanazawa, A., Kawamori, R., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.131 · Cited by 116
Self-citationPostprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koška, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 127
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Parkes, D. G., Mace, K. F., & TRAUTMANN, M. E. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 123
“In wild-type or apolipoprotein E-deficient mice, chronic exenatide administration inhibited monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve, possibly by inhibiting the inflammatory response in macrophages [82].”
BackgroundTherapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 123
“receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.”
BackgroundBeneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 120
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“One study in apolipoprotein E-deficient (apoE(2)/(2)) mice demonstrated that the GLP-1 receptor agonist exendin-4 suppressed the accumulation of monocyte and macrophages in the artery wall through the downregulation of various inflammatory and adhesion molecules on these cells (57).”
BackgroundGuo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., & Gu, X. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165826 · Cited by 112
“have indicated that LPS-induced macrophage activation and TNF-a expression was significantly reduced by GLP-1 analog exendin-4 through PKA/NF-kB signaling pathway (20).”
BackgroundMethodSteven, S., Jurk, K., Kopp, M., Kröller‐Schön, S., Mikhed, Y., Schwierczek, K., Roohani, S., Kashani, F., Oelze, M. W., Klein, T., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13549 · Cited by 117
“demonstrated anti-atherosclerotic and anti-inflammatory effects of GLP-1 in mice, which contribute to the inhibition of NFκB/p65 nuclear translocation by increased cAMP levels in macrophages (Arakawa et al., 2010; Matsubara et al., 2012).”
BackgroundDiabetes and COVID-19: The past, the present, and the future
Pranata, R., Henrina, J., Raffaello, W. M., Lawrensia, S., & Huang, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154814 · Cited by 121
“Aside from the glucose lowering effect, GLP1 reduces the accumulation of monocyte to various tissues and regulate the inflammation in macrophage, therefore attenuating atherosclerosis [83].”
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.043 · Cited by 111
“For instance, the GLP-1R agonist exendin-4 improved atherosclerosis by reducing macrophage adhesion to endothelial cells, as well as by reducing serum glucose levels.(32) GLP-1 peptide treatment decreased irradiationor LPS-induced proinflammatory cytokine expression in the brain and astrocytes in a mouse model.”
Zhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106
“[24] showed that LPS-induced macrophage activation and TNF-α expression was significantly reduced by”
BackgroundHeuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J. T., Sourij, H., Doran, Z., Keenan, J. F., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 108
Jojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105
Inoue, T., Inoguchi, T., Sonoda, N., Hendarto, H., Makimura, H., Sasaki, S., Yokomizo, H., Fujimura, Y., Miura, D., & Takayanagi, R. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.026 · Cited by 108
Goldney, J., Sargeant, J. A., & Davies, M. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05988-3 · Cited by 100
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
“…and liraglutide attenuated the development of atherosclerosis and cardiac dysfunction in mice, actions that were associated with reduced vascular monocyte adhesion and/or macrophage infiltration within blood vessels (Arakawa et al., 2010; Nagashima et al., 2011; Noyan-Ashraf et al., 2013).”
BackgroundGlucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
Iwaya, C., Nomiyama, T., Komatsu, S., Kawanami, T., Tsutsumi, Y., Hamaguchi, Y., Horikawa, T., Yoshinaga, Y., Yamashita, S.-I., Tanaka, T., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00461 · Cited by 100
Self-citationKelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-64 · Cited by 98
“Moreover, evidence suggests that GLP-1 may act directly on the endothelium to improve endothelial function and inhibit atherosclerosis [16-21] and may have additional beneficial cardiovascular effects [22,23].”
BackgroundVittone, F., Liberman, A., Vasic, D., Ostertag, R., Esser, M., Walcher, D., Ludwig, A., Marx, N., & Burgmaier, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2582-5 · Cited by 97
“Another study showed that treatment with the GLP-1 receptor agonist exendin-4 was associated with a reduction in monocyte adhesion on endothelial cells and a decrease in lesion size in Apoe mice [32].”
Impact of hyperglycemia on immune cell function: a comprehensive review
Lee, H., Kim, M.-J., Lee, I.-K., Hong, C.-W., & Jeon, J. (2024) · Diabetology International · doi:10.1007/s13340-024-00741-6 · Cited by 109
“Furthermore, GLP-1 receptor agonists such as exendin-4 inhibit monocyte adhesion to endothelial cells and attenuate atherosclerotic lesion development by suppressing the expression of pro-inflammatory cytokines in macrophages [144].”
Metadata
- Authors
- Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
- Affiliations
- Juntendo University (JP)
- Corresponding author
- Mita, Tomoya
- Watada, Hirotaka
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-12
- Volume
- 59
- Issue
- 4
- Pages
- 1030-1037
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2844811
- OpenAlex
- W2142097676
- Cited by
- 548
- References
- 38
- Citations by year
- 2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
- MeSH terms
- Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.